Relmada Therapeutics, Inc. (RLMD) Q4 FY25 Earnings Call

Strong Phase 2 durability supports mid-2026 Phase 3 launch, but registration and execution risks remain.

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Length35 minutes
EPS$-0.27
EPS consensus$-0.14

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26 · Q1 FY26 · Q3 FY25 · Q2 FY25

All RLMD earnings · Back to RLMD overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.